Truist analyst David MacDonald raised the firm’s price target on Quest Diagnostics (DGX) to $182 from $172 and keeps a Hold rating on the shares. The company’s organic revenue was up 5%, utilization remains solid, and Truist expects ongoing testing volume and robust 2024 M&A activity to provide an attractive tailwind, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DGX:
- Quest Diagnostics price target raised to $189 from $184 at Baird
- Quest Diagnostics price target raised to $175 from $168 at Barclays
- Quest Diagnostics Reports Strong Growth and Future Confidence
- Morning Movers: UPS and Cigna plunge double digits following Q4 results
- Quest Diagnostics increases quarterly dividend 6.7% to 80c per share